The American Heart Association (AHA) released the 2017 American Heart Association Focused Update on Adult Basic Life Support and Cardiopulmonary Resuscitation Quality (2017 AHA guidelines update) in November 2017. The 2017 AHA guidelines update was updated according to the rules named " the update of the guideline is no longer released every five years, but whenever new evidence is available” in the 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. The updated content in this guideline included five parts: dispatch-assisted cardiopulmonary resuscitation (CPR), bystander CPR, emergency medical services - delivered CRP, CRP for cardiac arrest, and chest compression - to - ventilation ratio. This review will interpret the 2017 AHA guidelines update in detail.
Sepsis is a critical condition. The key factor affecting the survival of patient is whether standard treatment can be obtained timely. Because of the complexity of its pathogenesis and high heterogeneity, there is no special diagnosis method currently. Early identification is difficult. Delayed diagnosis and treatment is closely related to the mortality of patients. With the continuous updating of the guidelines, sepsis has been included in the “time window” disease, putting forward a great challenge to the early screening and evaluation of sepsis. This article aims to review the application of Sepsis-Related Organ Failure Assessment, sepsis biomarkers and artificial intelligence algorithms in early screening and evaluation of sepsis, so as to provide guidance tools for timely starting standardized treatment of sepsis.
With the in-depth understanding of the severe acute respiratory syndrome coronavirus 2, it has been found that the virus not only causes serious damage to the human respiratory system, but also damages the kidney system, which can be manifested as acute kidney injury, and in severe cases, renal failure can occur. Patients with coronavirus disease 2019 and chronic kidney disease are at higher risk of worsening their condition and even death. Therefore, early recognition and intervention of renal injury is particularly important for prognosis. In this paper, the clinical data of renal injury in patients with coronavirus disease 2019 were reviewed, and the possible pathogenesis, incidence, clinical features, diagnosis and treatment were proposed for reference in clinical decision-making.
目的 探讨脓毒症患者的病情预后与高密度脂蛋白（HDL）之间的关联性。 方法 2008年3月1日－2010年2月28日选择50例严重脓毒症患者（脓毒症组）和30例非脓毒症的健康人（对照组），比较两组急性生理学与慢性健康状况评分Ⅱ（APACHEⅡ）和HDL水平。 结果 脓毒症组的HDL水平为（1.10 ± 0.39）mmol/L，对照组HDL水平为（1.61 ± 0.42） mmol/L，两组差异有统计学意义（t=6.786，P=0.000）。多因素非条件logistic回归分析显示，HDL水平（OR=0.877，P=0.025）和APACHEⅡ评分（OR=15.556，P=0.009）是影响脓毒症患者患病程度的两个有效独立因素。 结论 脓毒症能够导致患者的脂代谢出现紊乱，HDL水平是评估脓毒症患病程度的较好指标。
Psilocybin is a hallucinogenic indole alkaloid derived from mushrooms, which is metabolized into psilocin in vivo and exerts biological effects. Clinical studies have shown that psilocybin has the effect of relieving anxiety and depression in cancer patients. Due to its fast onset, significant therapeutic effect, and low addictive nature, psilocybin has the potential to break through the bottleneck of slow action and poor efficacy of existing depression drugs, bringing new hope for the treatment of severe depression and refractory depression. This article will review the pharmacokinetics, antidepressant mechanisms, and research progress of psilocybin, providing a reference for subsequent research.